Literature DB >> 9057360

Implications for immunosurveillance of altered HLA class I phenotypes in human tumours.

F Garrido1, F Ruiz-Cabello, T Cabrera, J J Pérez-Villar, M López-Botet, M Duggan-Keen, P L Stern.   

Abstract

HLA class I downregulation is a frequent event associated with tumour invasion and development. Altered HLA class I tumour phenotypes can have profound effects on T-cell and natural killer (NK)-cell antitumour responses. Here, Federico Garrido and colleagues analyse these altered tumour phenotypes in detail, indicating their potential relevance for implementation of immunotherapeutic protocols and strategies to overcome tumour escape mechanisms.

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9057360     DOI： 10.1016/s0167-5699(96)10075-x

Source DB:  PubMed          Journal:  Immunol Today        ISSN： 0167-5699


  150 in total

Review 1.  T cell receptor usage in malignant diseases.

Authors:  E Halapi; M Jeddi-Tehrani; A Osterborg; H Mellstedt
Journal:  Springer Semin Immunopathol       Date:  1999

2.  Molecular dynamics of MHC genesis unraveled by sequence analysis of the 1,796,938-bp HLA class I region.

Authors:  T Shiina; G Tamiya; A Oka; N Takishima; T Yamagata; E Kikkawa; K Iwata; M Tomizawa; N Okuaki; Y Kuwano; K Watanabe; Y Fukuzumi; S Itakura; C Sugawara; A Ono; M Yamazaki; H Tashiro; A Ando; T Ikemura; E Soeda; M Kimura; S Bahram; H Inoko
Journal:  Proc Natl Acad Sci U S A       Date:  1999-11-09       Impact factor: 11.205

3.  Natural killer cell acceptance of H-2 mismatch bone marrow grafts in transgenic mice expressing HLA-Cw3 specific killer cell inhibitory receptor.

Authors:  A Cambiaggi; C Verthuy; P Naquet; F Romagné; P Ferrier; R Biassoni; A Moretta; L Moretta; E Vivier
Journal:  Proc Natl Acad Sci U S A       Date:  1997-07-22       Impact factor: 11.205

Review 4.  Unravelling natural killer cell function: triggering and inhibitory human NK receptors.

Authors:  Lorenzo Moretta; Alessandro Moretta
Journal:  EMBO J       Date:  2003-12-18       Impact factor: 11.598

5.  Identification of 4Ig-B7-H3 as a neuroblastoma-associated molecule that exerts a protective role from an NK cell-mediated lysis.

Authors:  Roberta Castriconi; Alessandra Dondero; Raffaella Augugliaro; Claudia Cantoni; Barbara Carnemolla; Angela Rita Sementa; Francesca Negri; Romana Conte; Maria Valeria Corrias; Lorenzo Moretta; Alessandro Moretta; Cristina Bottino
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-16       Impact factor: 11.205

Review 6.  Generation of natural killer cells from hematopoietic stem cells in vitro for immunotherapy.

Authors:  Martha Luevano; Alejandro Madrigal; Aurore Saudemont
Journal:  Cell Mol Immunol       Date:  2012-06-18       Impact factor: 11.530

7.  Analysis of HLA-ABC locus-specific transcription in normal tissues.

Authors:  Ana Belén García-Ruano; Rosa Méndez; José María Romero; Teresa Cabrera; Francisco Ruiz-Cabello; Federico Garrido
Journal:  Immunogenetics       Date:  2010-09-15       Impact factor: 2.846

8.  Targeting sarcoma tumor-initiating cells through differentiation therapy.

Authors:  Dan Han; Veronica Rodriguez-Bravo; Elizabeth Charytonowicz; Elizabeth Demicco; Josep Domingo-Domenech; Robert G Maki; Carlos Cordon-Cardo
Journal:  Stem Cell Res       Date:  2017-04-13       Impact factor: 2.020

9.  Distribution of HLA class I altered phenotypes in colorectal carcinomas: high frequency of HLA haplotype loss associated with loss of heterozygosity in chromosome region 6p21.

Authors:  Isabel Maleno; Carmen Maria Cabrera; Teresa Cabrera; Laura Paco; Miguel Angel López-Nevot; Antonia Collado; Antonio Ferrón; Federico Garrido
Journal:  Immunogenetics       Date:  2004-07-16       Impact factor: 2.846

10.  HLA class I alterations in breast carcinoma are associated with a high frequency of the loss of heterozygosity at chromosomes 6 and 15.

Authors:  María A Garrido; Teresa Rodriguez; Svitlana Zinchenko; Isabel Maleno; Francisco Ruiz-Cabello; Ángel Concha; Nicolás Olea; Federico Garrido; Natalia Aptsiauri
Journal:  Immunogenetics       Date:  2018-08-25       Impact factor: 2.846
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.